about
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskNeutralization of endogenous vascular endothelial growth factor depletes primordial follicles in the mouse ovaryA phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236)Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur.Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates.Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancerMulticenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.Current and emerging trends in Lynch syndrome identification in women with endometrial cancer.The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.New innovations in cervical cancer screening.Ureteroileoneocystostomy: the use of an ileal segment for ureteral substitution in gynecologic oncology.SGO White Paper on ovarian cancer: etiology, screening and surveillance.Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesTargeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitorAberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.Immunization with synthetic VEGF peptides in ovarian cancerPolymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group StudyIs bariatric surgery an option for women with gynecologic cancer? Examining weight loss counseling practices and training among gynecologic oncology providers.Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.Long-chain ω-3 fatty acid intake and endometrial cancer risk in the Women's Health InitiativeA cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients.Gynecologic malignancies in adolescents.Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian CancerNoncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivoWWP2 and its association with PTEN in endometrial cancerThe cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
P50
Q27008356-6DE2B842-7DCC-433B-914A-CC23D4006390Q28590064-E0D2055D-120E-4115-8BD5-98BD9BF94879Q30275176-C163B63A-0882-452C-9224-9A14179371BEQ30278760-CF1967C1-DA08-4B86-A59C-5C21048A3D2CQ30361969-A5B20D39-9127-4C39-A0D3-380948D845D4Q30408170-EB6A3778-3534-4B46-8BF9-6F7D7ABEA351Q30413346-87F595C8-EFEB-4137-8D35-DD432BA95670Q30429122-63B7C034-7A90-41DC-9FE3-193E61F77BEAQ30455725-65B2CF4A-49AD-4BBA-B9D6-C14551572B20Q31032652-31F82C65-1933-4213-A1F6-3CDE657D7BAFQ33292774-8DDA7658-E765-4F11-A3DB-52A1EB107261Q33342752-CD8BE7D8-63AB-49C8-A207-B96876A2BC09Q33381373-8684C856-0D81-4F0E-B0C2-2B2F9C5E5B77Q33397995-F5F42173-826B-4049-9154-BA2C6A17F5EAQ33407093-C595EB34-943E-4585-99C5-EED1C30B841CQ33415805-BFC06ED5-65F6-4D3C-9CA6-75E24008A55BQ33738168-24B6A5EB-E8AD-4A02-808B-AB0EB06F9766Q33794108-EC5CB3CA-72A9-4B8F-B88E-D966E9D323CAQ34023517-91A1F3D0-4ED8-44DB-BDBB-9E6E719BCA06Q34422847-FB378B70-CB05-40D2-8BB6-68665D5F1483Q34465876-80BB5D50-C76E-4337-A7AE-C9B715A93507Q34622294-FC8EB6DB-CD56-4C53-8B37-B7D021A3F85DQ34678905-3528373B-B2E8-48C8-901B-E67BCC7F12EDQ34763999-A9BC7564-8431-4CD0-A434-A7727399B067Q34781159-CF5464D7-F2B8-4978-8000-E1D8593B0172Q34819689-D9D94C90-8A2E-46BC-AF85-5F33DD106FCCQ34901858-A6F123C5-8348-468C-9EC5-C884F5B3602BQ35007615-85F1BFDB-D890-4A14-86A4-F15FD165CCBBQ35033234-3E293CF9-9FA3-478E-9709-02BEACC79E40Q35174701-DF324604-E7BC-4692-A398-3BAD655A2B9BQ35212074-C59385BD-765F-4AF2-A8DD-C6E06331E32BQ35239530-AC1FC2BB-3935-4C5C-B1CD-6B141D99943FQ35883007-152FDF7B-BB9E-4B9D-B6E8-6FE3952F5BE6Q35974623-C64E0543-E757-433F-8C6A-19A9AE3B3EA5Q35996667-02465308-3EB2-4251-B8D2-77F3F343235AQ36011137-6472429F-5CAC-4CF7-8B18-1BD00646CE21Q36032452-AA1A249C-2419-44E6-9778-300EF556BA5BQ36039871-81B7E8C5-4563-4CD1-800B-34FDA8FD8443Q36040641-4C86BE94-087A-4DFA-8C88-5246ACEDA1B9Q36087170-C6221BC8-5F9F-452D-A863-79DEBA059968
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David E Cohn
@nl
David E Cohn
@sl
David E. Cohn
@en
David E. Cohn
@es
type
label
David E Cohn
@nl
David E Cohn
@sl
David E. Cohn
@en
David E. Cohn
@es
altLabel
David Cohn
@en
prefLabel
David E Cohn
@nl
David E Cohn
@sl
David E. Cohn
@en
David E. Cohn
@es
P106
P1153
7202567650
P21
P31
P3835
david-cohn2
P496
0000-0002-3036-6172